Proteasome inhibition in combination with immunotherapies: State-of-the-Art in multiple myeloma.

[1]  K. Griffith,et al.  Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial. , 2023, The Lancet. Oncology.

[2]  A. Krishnan,et al.  Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma. , 2022, The New England journal of medicine.

[3]  P. Sonneveld,et al.  Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  A. Jakubowiak,et al.  Elranatamab, a BCMA Targeted T-Cell Engaging Bispecific Antibody, Induces Durable Clinical and Molecular Responses for Patients with Relapsed or Refractory Multiple Myeloma , 2022, Blood.

[5]  P. Sonneveld,et al.  Efficacy of Daratumumab Combined with Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting with Extramedullary Disease: A European Myeloma Network Study (EMN19) , 2022, Blood.

[6]  A. Jakubowiak,et al.  Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent: A Phase 2 Measurable Residual Disease-Adapted Study. , 2022, JAMA oncology.

[7]  P. Hari,et al.  Multicenter phase II, double-blind placebo-controlled trial of maintenance ixazomib after allogeneic transplantation for high-risk multiple myeloma: Results of the BMT CTN 1302 Trial. , 2022, Transplantation and cellular therapy.

[8]  J. Burke,et al.  Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for multiple myeloma: final results of the LYRA study , 2022, Leukemia & lymphoma.

[9]  H. Einsele,et al.  Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient? , 2022, Journal of Hematology & Oncology.

[10]  S. Jagannath,et al.  Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma. , 2022, The New England journal of medicine.

[11]  Minya Pu,et al.  Phase II study of the combination of daratumumab, ixazomib, pomalidomide, and dexamethasone as salvage therapy in relapsed/refractory multiple myeloma: Stage 2 interim results. , 2022, Journal of Clinical Oncology.

[12]  J. Opalinska,et al.  Oral Abstract: MM-459 Safety and Clinical Activity of Belantamab Mafodotin with Lenalidomide Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): DREAMM-6 Arm-A Interim Analysis , 2022, Clinical Lymphoma Myeloma and Leukemia.

[13]  O. Decaux,et al.  Daratumumab carfilzomib lenalidomide and dexamethasone as induction therapy in high-risk, transplant-eligible patients with newly diagnosed myeloma: Results of the phase 2 study IFM 2018-04. , 2022, Journal of Clinical Oncology.

[14]  C. Bokemeyer,et al.  P926: DARATUMUMAB, BORTEZOMIB AND DEXAMETHASONE FOR TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND SEVERE RENAL IMPAIRMENT: RESULTS FROM THE PHASE 2 GMMG-DANTE TRIAL , 2022, HemaSphere.

[15]  S. Rajkumar,et al.  Multiple myeloma: 2022 update on diagnosis, risk stratification, and management , 2022, American journal of hematology.

[16]  K. Rezvani,et al.  KRD vs. VRD as induction before autologous hematopoietic progenitor cell transplantation for high-risk multiple myeloma , 2022, Bone Marrow Transplantation.

[17]  M. Vekemans,et al.  Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study. , 2022, Blood.

[18]  T. Love,et al.  Autoimmunity, Infections, and the Risk of Monoclonal Gammopathy of Undetermined Significance , 2022, Frontiers in Immunology.

[19]  T. Spektor,et al.  A phase 1/2 study of ixazomib in place of bortezomib or carfilzomib in a subsequent line of therapy for patients with multiple myeloma refractory to their last bortezomib or carfilzomib combination regimen. , 2022, Experimental hematology.

[20]  M. Mohty,et al.  All-oral triplet combination of ixazomib, lenalidomide, and dexamethasone in newly diagnosed transplant-eligible multiple myeloma patients: final results of the phase II IFM 2013-06 study , 2022, Haematologica.

[21]  J. Laubach,et al.  Phase 2 studies of lenalidomide, subcutaneous bortezomib, and dexamethasone as induction therapy in patients with newly diagnosed multiple myeloma , 2022, American journal of hematology.

[22]  M. Offidani,et al.  Autologous Stem Cell Transplantation in Multiple Myeloma: Where Are We and Where Do We Want to Go? , 2022, Cells.

[23]  A. Jemal,et al.  Cancer statistics, 2022 , 2022, CA: a cancer journal for clinicians.

[24]  A. Kisselev.  Site-Specific Proteasome Inhibitors , 2021, Biomolecules.

[25]  P. Hari,et al.  Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  M. Dimopoulos,et al.  Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study. , 2021, The Lancet. Oncology.

[27]  R. Orlowski,et al.  Safety and Efficacy of Combination Maintenance Therapy with Ixazomib and Lenalidomide in Patients with Posttransplant Myeloma , 2021, Clinical cancer research : an official journal of the American Association for Cancer Research.

[28]  M. Dimopoulos,et al.  CC-92480, a Potent, Novel Cereblon E3 Ligase Modulator (CELMoD) Agent, in Combination with Dexamethasone (DEX) and Bortezomib (BORT) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results from the Phase 1/2 Study CC-92480-MM-002 , 2021, Blood.

[29]  K. de Heer,et al.  Ixazomib, Daratumumab and Low Dose Dexamethasone in Intermediate-Fit Patients with Newly Diagnosed Multiple Myeloma (NDMM); Results of Induction Treatment of the Phase II HOVON 143 Study , 2021, Blood.

[30]  D. Hose,et al.  Elotuzumab in Combination with Lenalidomide, Bortezomib, Dexamethasone and Autologous Transplantation for Newly-Diagnosed Multiple Myeloma: Results from the Randomized Phase III GMMG-HD6 Trial , 2021, Blood.

[31]  H. Goldschmidt,et al.  Addition of Isatuximab to Lenalidomide, Bortezomib and Dexamethasone As Induction Therapy for Newly-Diagnosed, Transplant-Eligible Multiple Myeloma Patients: The Phase III GMMG-HD7 Trial , 2021, Blood.

[32]  O. Decaux,et al.  Daratumumab Plus Ixazomib, Lenalidomide, and Dexamethasone As Extended Induction and Consolidation Followed By Lenalidomide Maintenance in Standard-Risk Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (IFM 2018-01): A Phase II Study of the Intergroupe Francophone Du Myélome (IFM , 2021, Blood.

[33]  H. Goldschmidt,et al.  Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: interim analysis of the GMMG-CONCEPT trial , 2021, Leukemia.

[34]  R. A. Fan,et al.  Proteasome Inhibitors and Their Pharmacokinetics, Pharmacodynamics, and Metabolism , 2021, International journal of molecular sciences.

[35]  K. Rezvani,et al.  Real-world long-term outcomes in multiple myeloma with VRD induction, Mel200-conditioned auto-HCT, and lenalidomide maintenance , 2021, Leukemia & lymphoma.

[36]  Zhong-xia Huang,et al.  Ixazomib‐based maintenance therapy after bortezomib‐based induction in patients with multiple myeloma not undergoing transplantation: A real‐world study , 2021, Cancer medicine.

[37]  Yan Yang,et al.  Minimal residual disease in multiple myeloma: current status , 2021, Biomarker Research.

[38]  S. Iida,et al.  A phase 2, open-label, multicenter study of ixazomib plus lenalidomide and dexamethasone in adult Japanese patients with relapsed and/or refractory multiple myeloma , 2021, International Journal of Clinical Oncology.

[39]  R. Fu,et al.  P978: IXAZOMIB VERSUS LENALIDOMIDE OR IXAZOMIB AND LENALIDOMIDE COMBINATION AS MAINTENANCE REGIMEN FOR PATIENTS WITH MULTIPLE MYELOMA: INTERIM ANALYSIS OF A MULTI-CENTER PROSPECTIVE STUDY IN CHINA , 2021, HemaSphere.

[40]  Jianxiang Wang,et al.  P-163: Efficacy and safety of Daratumumab, Bortezomib, Melphalan, and Prednisone (D-VMP) versus Bortezomib, Melphalan, and Prednisone (VMP) in Chinese patients with newly diagnosed Multiple Myeloma: OCTANS , 2021, Clinical Lymphoma Myeloma and Leukemia.

[41]  J. Laubach,et al.  A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202) , 2021, American journal of hematology.

[42]  C. Wallington-Beddoe,et al.  Prognostic and predictive biomarker developments in multiple myeloma , 2021, Journal of Hematology & Oncology.

[43]  H. Nahi,et al.  Carfilzomib and dexamethasone maintenance following salvage ASCT in multiple myeloma: A randomised phase 2 trial by the Nordic Myeloma Study Group , 2021, European journal of haematology.

[44]  S. Steinberg,et al.  Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Maintenance for Prevention of Symptomatic Multiple Myeloma in Patients With High-risk Smoldering Myeloma: A Phase 2 Nonrandomized Controlled Trial. , 2021, JAMA oncology.

[45]  M. Dimopoulos,et al.  Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  P. Ganly,et al.  Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  M. Dimopoulos,et al.  Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial , 2021, The Lancet.

[48]  K. Kim.  Proteasomal adaptations to FDA-approved proteasome inhibitors: a potential mechanism for drug resistance? , 2021, Cancer drug resistance.

[49]  Shaji K. Kumar,et al.  ECOG-ACRIN EAA181: Effective quadruplet utilization after treatment evaluation (EQUATE)—a randomized phase 3 trial for newly diagnosed multiple myeloma (NDMM) not intended for early autologous transplantation. , 2021 .

[50]  A. El-Khoueiry,et al.  A first-in-human study of AO-176, a highly differentiated anti-CD47 antibody, in patients with advanced solid tumors. , 2021 .

[51]  C. Wallington-Beddoe,et al.  A phase II trial of continuous ixazomib, thalidomide and dexamethasone for relapsed and/or refractory multiple myeloma: the Australasian Myeloma Research Consortium (AMaRC) 16‐02 trial , 2021, British journal of haematology.

[52]  Xiao-jun Huang,et al.  Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Chinese Patients with Relapsed or Refractory Multiple Myeloma: Phase 3 LEPUS (MMY3009) Study. , 2021, Clinical lymphoma, myeloma & leukemia.

[53]  S. Holstein,et al.  Evolution of Treatment Paradigms in Newly Diagnosed Multiple Myeloma , 2021, Drugs.

[54]  M. Arcila,et al.  Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma: The MANHATTAN Nonrandomized Clinical Trial. , 2021, JAMA oncology.

[55]  S. Lonial,et al.  Oral ixazomib, lenalidomide, and dexamethasone for newly diagnosed transplant-ineligible multiple myeloma patients. , 2021, Blood.

[56]  S. Jagannath,et al.  Phase 1b trial of isatuximab, an anti‐CD38 monoclonal antibody, in combination with carfilzomib as treatment of relapsed/refractory multiple myeloma , 2021, Cancer.

[57]  P. Sonneveld,et al.  Health‐related quality of life maintained over time in patients with relapsed or refractory multiple myeloma treated with daratumumab in combination with bortezomib and dexamethasone: results from the phase III CASTOR trial , 2021, British journal of haematology.

[58]  T. Zimmerman,et al.  Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial. , 2021, The Lancet. Haematology.

[59]  K. Yong,et al.  Multiple myeloma , 2021, The Lancet.

[60]  M. Gobbi,et al.  Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study. , 2020, The Lancet. Haematology.

[61]  H. Goldschmidt,et al.  Front-line daratumumab-VTd versus standard-of-care in ASCT-eligible multiple myeloma: matching-adjusted indirect comparison. , 2020, Immunotherapy.

[62]  H. Goldschmidt,et al.  Carfilzomib 56 mg/m2 twice-weekly in combination with dexamethasone and daratumumab (KdD) versus daratumumab in combination with bortezomib and dexamethasone (DVd): a matching-adjusted indirect treatment comparison , 2020, Leukemia & lymphoma.

[63]  P. Voorhees,et al.  Response-Adaptive Phase II Study of Daratumumab Combined with Carfilzomib, Lenalidomide and Dexamethasone in Newly Diagnosed Multiple Myeloma , 2020 .

[64]  L. Qiu,et al.  The Relative Risk of Prognostic Factors of Age Stratified Multiple Myeloma , 2020 .

[65]  H. Nahi,et al.  A Prospective Phase 2 Study to Assess Minimal Residual Disease after Ixazomib, Lenalidomide and Dexamethasone Treatment for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients , 2020 .

[66]  A. Jakubowiak,et al.  Aggressive Smoldering Curative Approach Evaluating Novel Therapies (ASCENT): A Phase 2 Trial of Induction, Consolidation and Maintenance in Subjects with High Risk Smoldering Multiple Myeloma (SMM): Initial Analysis of Safety Data , 2020 .

[67]  Yang Bai,et al.  Updates to the drug‐resistant mechanism of proteasome inhibitors in multiple myeloma , 2020, Asia-Pacific journal of clinical oncology.

[68]  R. Hájek,et al.  Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice , 2020, BMC cancer.

[69]  S. Iida,et al.  Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open‐label Phase II study , 2020, British journal of haematology.

[70]  S. Jagannath,et al.  A phase Ib study of TAK-079, an investigational anti-CD38 monoclonal antibody (mAb) in patients with relapsed/ refractory multiple myeloma (RRMM): Preliminary results. , 2020 .

[71]  N. Geller,et al.  Long-term follow-up of BMT CTN 0702 (STaMINA) of postautologous hematopoietic cell transplantation (autoHCT) strategies in the upfront treatment of multiple myeloma (MM). , 2020 .

[72]  H. Einsele,et al.  Bortezomib, lenalidomide, and dexamethasone (VRD) is superior to lenalidomide, adriamycin, and dexamethasone (RAD) prior to risk-adapted transplant in newly diagnosed myeloma. , 2020 .

[73]  E. Terpos,et al.  DREAMM-9: Phase III study of belantamab mafodotin plus VRd versus VRd alone in transplant-ineligible newly diagnosed multiple myeloma (TI NDMM). , 2020 .

[74]  P. Moreau,et al.  Updates from a phase Ib study of isatuximab (Isa), bortezomib (V) and dexamethasone (D) plus cyclophosphamide (C) or lenalidomide (R) in transplant-ineligible, newly diagnosed multiple myeloma (NDMM). , 2020 .

[75]  C. Hofmeister,et al.  Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[76]  L. Fricker.  Proteasome Inhibitor Drugs. , 2020, Annual review of pharmacology and toxicology.

[77]  Andre H Crepaldi,et al.  Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial , 2019, The Lancet.

[78]  F. Gao,et al.  Ixazomib or Lenalidomide Maintenance Following Autologous Stem Cell Transplantation and Ixazomib, Lenalidomide, and Dexamethasone (IRD) Consolidation in Patients with Newly Diagnosed Multiple Myeloma: Results from a Large Multi-Center Randomized Phase II Trial , 2019, Blood.

[79]  O. Linder,et al.  A Randomized Phase 2 Trial Comparing Carfilzomib-Dexamethasone Vs Observation As Maintenance after Induction with Carfilzomib-Cyclophosphamide-Dexamethasone in Salvage ASCT in Multiple Myeloma: A Trial By the Nordic Myeloma Study Group , 2019, Blood.

[80]  Andre H Crepaldi,et al.  Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Overall Survival in Alcyone , 2019, Blood.

[81]  A. Polonskaia,et al.  Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN , 2019, Leukemia.

[82]  L. Trippa,et al.  Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myeloma , 2019, American journal of hematology.

[83]  P. Sonneveld,et al.  Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR. , 2019, Clinical lymphoma, myeloma & leukemia.

[84]  A. Gnanasakthy,et al.  Quality of life is maintained with ixazomib maintenance in post‐transplant newly diagnosed multiple myeloma: The TOURMALINE‐MM3 trial , 2019, European journal of haematology.

[85]  R. Greil,et al.  Ixazomib–Thalidomide–Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma , 2019, British Journal of Cancer.

[86]  P. Sonneveld,et al.  Oprozomib in patients with newly diagnosed multiple myeloma , 2019, Blood Cancer Journal.

[87]  P. Sonneveld,et al.  Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study , 2019, The Lancet.

[88]  S. Naicker,et al.  CyBorD-DARA is potent initial induction for MM and enhances ADCP: initial results of the 16-BCNI-001/CTRIAL-IE 16-02 study. , 2019, Blood advances.

[89]  M. Beksac,et al.  Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. , 2019, The Lancet. Oncology.

[90]  S. Devlin,et al.  Ixazomib and dexamethasone in high risk smoldering multiple myeloma: a clinical and correlative pilot study , 2019, Leukemia & lymphoma.

[91]  B. Xin,et al.  Proteasome Inhibition in Multiple Myeloma: Head-to-Head Comparison of Currently Available Proteasome Inhibitors. , 2019, Cell chemical biology.

[92]  David M. Smith,et al.  A Practical Review of Proteasome Pharmacology , 2019, Pharmacological Reviews.

[93]  H. Prince,et al.  Phase 3 study of subcutaneous bortezomib, thalidomide, and prednisolone consolidation after subcutaneous bortezomib-based induction and autologous stem cell transplantation in patients with previously untreated multiple myeloma: the VCAT study , 2019, Leukemia & lymphoma.

[94]  P. Galieni,et al.  Once-weekly versus twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: a pooled analysis of two phase I/II studies , 2019, Haematologica.

[95]  S. Lonial,et al.  Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance , 2019, Leukemia.

[96]  N. Puig,et al.  Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd , 2018, Blood.

[97]  S. Lonial,et al.  Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial, PINR) , 2018, Blood.

[98]  A. Oriol,et al.  VTD (Bortezomib/Thalidomide/Dexamethasone) As Pretransplant Induction Therapy for Multiple Myeloma: Definitive Results of a Randomized Phase 3 Pethema/GEM Study , 2018, Blood.

[99]  N. Munshi,et al.  Phase II Trial of the Combination of Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma , 2018, Blood.

[100]  K. D. Sørensen,et al.  Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma , 2018, Nature Communications.

[101]  H. Goldschmidt,et al.  European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when , 2018, Haematologica.

[102]  M. Dimopoulos,et al.  Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study. , 2018, The Lancet. Oncology.

[103]  L. Trippa,et al.  A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant‐ineligible multiple myeloma , 2018, British journal of haematology.

[104]  P. Hari,et al.  Phase 1/2 Trial of Carfilzomib Plus High-Dose Melphalan Preparative Regimen for Salvage Autologous Hematopoietic Cell Transplantation Followed by Maintenance Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma. , 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[105]  C. Hofmeister,et al.  Twice‐weekly ixazomib in combination with lenalidomide‐dexamethasone in patients with newly diagnosed multiple myeloma , 2018, British journal of haematology.

[106]  J. Lohr,et al.  A phase II study of elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma. , 2018 .

[107]  A. Jakubowiak,et al.  Daratumumab (DARA) in combination with carfilzomib and dexamethasone (D-Kd) in lenalidomide (Len)-refractory patients (Pts) with relapsed multiple myeloma (MM): Subgroup analysis of MMY1001. , 2018 .

[108]  D. Siegel,et al.  Weekly carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed or refractory multiple myeloma (RRMM): A phase 1b study. , 2018 .

[109]  S. Iida,et al.  Safety and efficacy of daratumumab in combination with bortezomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma , 2018, International Journal of Hematology.

[110]  H. Goldschmidt,et al.  Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[111]  J. Cerhan,et al.  Long‐Term Follow‐up of Monoclonal Gammopathy of Undetermined Significance , 2018, The New England journal of medicine.

[112]  M. Boccadoro,et al.  Pharmacokinetic drug evaluation of ixazomib citrate for the treatment of multiple myeloma , 2018, Expert opinion on drug metabolism & toxicology.

[113]  D. Auclair,et al.  Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma , 2017, Leukemia.

[114]  Barbara A. Novak,et al.  A phase I/II study of KW-2478, an Hsp90 inhibitor, in combination with bortezomib in patients with relapsed/refractory multiple myeloma , 2017, British Journal of Cancer.

[115]  C. Hofmeister,et al.  Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma , 2017, Leukemia.

[116]  J. Miguel,et al.  Pembrolizumab (Pembro) plus lenalidomide (Len) and low-dose dexamethasone (Dex) for relapsed/refractory multiple myeloma (RRMM): Efficacy and biomarker analyses. , 2017 .

[117]  S. Lonial,et al.  An open-label, single arm, phase IIa study of bortezomib, lenalidomide, dexamethasone, and elotuzumab in newly diagnosed multiple myeloma. , 2017 .

[118]  R. Moss,et al.  Replacement of ixazomib for relapsed/refractory multiple myeloma patients refractory to a bortezomib or carfilzomib-containing combination therapy. , 2017 .

[119]  N. Munshi,et al.  Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma , 2017, The New England journal of medicine.

[120]  B. Barlogie,et al.  Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial , 2017, The Lancet.

[121]  R. Vij,et al.  Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma , 2017, Leukemia & lymphoma.

[122]  P. Richardson,et al.  Marizomib for CNS-Multiple Myeloma , 2016 .

[123]  M. Taniwaki,et al.  Dose‐escalation study of tabalumab with bortezomib and dexamethasone in Japanese patients with multiple myeloma , 2016, Cancer science.

[124]  H. Goldschmidt,et al.  International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. , 2016, The Lancet. Oncology.

[125]  Tuan S. Nguyen,et al.  Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma , 2016, Clinical Cancer Research.

[126]  Huyuan Yang,et al.  Pharmacokinetics of ixazomib, an oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairment , 2016, British journal of clinical pharmacology.

[127]  K. Griffith,et al.  Phase 1/2 study of carfilzomib, pomalidomide, and dexamethasone (KPd) in patients (Pts) with relapsed/refractory multiple myeloma (RRMM): A Multiple Myeloma Research Consortium multicenter study. , 2016 .

[128]  M. Dimopoulos,et al.  Carfilzomib, lenalidomide, and dexamethasone (KRd) vs lenalidomide and dexamethasone (Rd) in patients with relapsed multiple myeloma (RMM) and early progression during prior therapy: Secondary analysis from the phase 3 study ASPIRE (NCT01080391). , 2016 .

[129]  Huyuan Yang,et al.  A pharmacokinetics and safety phase 1/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end‐stage renal disease requiring haemodialysis , 2016, British journal of haematology.

[130]  A. Hui,et al.  The Effect of a High‐Fat Meal on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or Lymphoma , 2016, Journal of clinical pharmacology.

[131]  D. Esseltine,et al.  Pharmacokinetics and safety of ixazomib plus lenalidomide–dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 study , 2015, Journal of Hematology & Oncology.

[132]  S. Steinberg,et al.  Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma. , 2015, JAMA oncology.

[133]  Yuan-Xiao Zhu,et al.  Cereblon binding molecules in multiple myeloma. , 2015, Blood reviews.

[134]  Gordon Cook,et al.  Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[135]  R. Greil,et al.  Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5‐year follow‐up , 2015, British journal of haematology.

[136]  P. L. Bergsagel,et al.  Phase Ib/II trial of CYKLONE (cyclophosphamide, carfilzomib, thalidomide and dexamethasone) for newly diagnosed myeloma , 2015, British journal of haematology.

[137]  Alese E. Halvorson,et al.  Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma. , 2014, Blood.

[138]  P. Richardson,et al.  Phase Ib Study of the Novel Anti-CXCR4 Antibody Ulocuplumab (BMS-936564) in Combination with Lenalidomide Plus Low-Dose Dexamethasone, or with Bortezomib plus Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma , 2014 .

[139]  G. Tricot,et al.  Safety and efficacy of targeted-dose busulfan and bortezomib as a conditioning regimen for patients with relapsed multiple myeloma undergoing a second autologous blood progenitor cell transplantation. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[140]  A. Palumbo,et al.  Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma. , 2014, Blood.

[141]  S. Ševčíková,et al.  Proteasome inhibitors – molecular basis and current perspectives in multiple myeloma , 2014, Journal of cellular and molecular medicine.

[142]  D. Esseltine,et al.  A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma. , 2014, Blood.

[143]  M. Boccadoro,et al.  Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[144]  A. Verma,et al.  PK-Directed Intravenous Busulfan In Combination With High-Dose Melphalan and Bortezomib As Conditioning Regimen For Patients With Multiple Myeloma , 2013 .

[145]  L. Crawford,et al.  Targeting the ubiquitin proteasome system in haematological malignancies. , 2013, Blood reviews.

[146]  Michael L. Wang,et al.  Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. , 2013, Blood.

[147]  J. Berenson,et al.  Results of a phase I/II study (NCT01365559) of carfilzomib (CFZ) replacing bortezomib (BTZ) in BTZ-containing regimens for BTZ-treated patients (pts) with relapsed and refractory multiple myeloma (MM). , 2013 .

[148]  M. Kaminski,et al.  Treatment outcome with the combination of carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) for newly diagnosed multiple myeloma (NDMM) after extended follow-up. , 2013 .

[149]  H. Jim,et al.  Allogeneic hematopoietic cell transplantation for consolidation of VGPR or CR for newly diagnosed multiple myeloma , 2013, Bone Marrow Transplantation.

[150]  R. Vij,et al.  Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety , 2013, Leukemia.

[151]  K. Papadopoulos,et al.  Clinical Pharmacokinetics, Metabolism, and Drug-Drug Interaction of Carfilzomib , 2013, Drug Metabolism and Disposition.

[152]  H. van de Velde,et al.  Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma , 2012, Haematologica.

[153]  I. Flinn,et al.  Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. , 2012, Blood.

[154]  R. Neuwirth,et al.  Pharmacokinetics and Safety of Bortezomib in Patients with Advanced Malignancies and Varying Degrees of Liver Dysfunction: Phase I NCI Organ Dysfunction Working Group Study NCI-6432 , 2012, Clinical Cancer Research.

[155]  C. Chen,et al.  A phase 2 study of pegylated liposomal doxorubicin, bortezomib, dexamethasone and lenalidomide for patients with relapsed/refractory multiple myeloma , 2012, Leukemia.

[156]  B. Pégourié,et al.  Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma. , 2011, Blood.

[157]  M. Bennett,et al.  Pharmacokinetics, Pharmacodynamics, Metabolism, Distribution, and Excretion of Carfilzomib in Rats , 2011, Drug Metabolism and Disposition.

[158]  M. Kaminski,et al.  Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial. , 2011, Blood.

[159]  M. Czuczman,et al.  A steroid‐independent regimen of bortezomib, liposomal doxorubicin and thalidomide demonstrate high response rates in newly diagnosed multiple myeloma patients , 2011, British journal of haematology.

[160]  M Boccadoro,et al.  Phase I study of the anti insulin-like growth factor 1 receptor (IGF-1R) monoclonal antibody, AVE1642, as single agent and in combination with bortezomib in patients with relapsed multiple myeloma , 2011, Leukemia.

[161]  R. Neuwirth,et al.  Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study , 2011, Cancer Chemotherapy and Pharmacology.

[162]  A. Berger,et al.  Preclinical evaluation of the antitumor activity of bortezomib in combination with vitamin C or with epigallocatechin gallate, a component of green tea , 2011, Cancer Chemotherapy and Pharmacology.

[163]  Mourad Tighiouart,et al.  A Phase I/II Trial Combining High-Dose Melphalan and Autologous Transplant with Bortezomib for Multiple Myeloma: A Dose- and Schedule-Finding Study , 2010, Clinical Cancer Research.

[164]  D. Esseltine,et al.  Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. , 2010, Blood.

[165]  J. H. Lee,et al.  Bortezomib, thalidomide, dexamethasone induction therapy followed by melphalan, prednisolone, thalidomide consolidation therapy as a first line of treatment for patients with multiple myeloma who are non-transplant candidates: results of the Korean Multiple Myeloma Working Party (KMMWP) , 2010, Annals of Hematology.

[166]  P. L. Bergsagel,et al.  Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma. , 2010, Blood.

[167]  N. Munshi,et al.  Dacetuzumab (SGN-40), Lenalidomide, and Weekly Dexamethasone in Relapsed or Refractory Multiple Myeloma: Multiple Responses Observed in a Phase 1b Study. , 2009 .

[168]  D. Esseltine,et al.  Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[169]  Thomas C. Chen,et al.  Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid-based proteasome inhibitors. , 2009, Blood.

[170]  T. Therneau,et al.  Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significance. , 2008, Blood.

[171]  R. Neuwirth,et al.  Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[172]  G. Opelz,et al.  Proteasome inhibition suppresses essential immune functions of human CD4+ T cells , 2008, Immunology.

[173]  Beverly S Mitchell,et al.  Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[174]  P. Elliott,et al.  The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. , 2001, Cancer research.

[175]  A. Tong,et al.  CD40 and the effect of anti-CD40-binding on human multiple myeloma clonogenicity. , 1996, Leukemia & lymphoma.

[176]  Aaron Ciechanover,et al.  The ubiquitin-proteasome proteolytic pathway , 1994, Cell.

[177]  Michael L. Wang,et al.  Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. , 2015, The New England journal of medicine.

[178]  O. Cope,et al.  Multiple myeloma. , 1948, The New England journal of medicine.